Endocrine-Related Cancer

References

1. ↵
   1. Aas T,
   2. Borresen AL,
   3. Geisler S,
   4. Smith-Sorensen B,
   5. Johnsen H,
   6. Varhaug JE,
   7. Akslen LA &
   8. Lønning PE

   1996 Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine 2 811–814.
2. ↵
   1. Acosta JJ,
   2. Munoz RM,
   3. Gonzalez L,
   4. Subtil-Rodriguez A,
   5. Dominguez-Caceres MA,
   6. Garcia-Martinez JM,
   7. Calcabrini A,
   8. Lazaro-Trueba I &
   9. Martin-Perez J

   2003 Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. Molecular Endocrinology 17 2268–2282.
3. ↵
   1. Ambrosone CB,
   2. Sweeney C,
   3. Coles BF,
   4. Thompson PA,
   5. McClure GY,
   6. Korourian S,
   7. Fares MY,
   8. Stone A,
   9. Kadlubar FF &
   10. Hutchins LF

   2001 Polymorphisms in glutathione-S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Research 61 7130–7135.
4. ↵
   1. Ariazi EA &
   2. Jordan VC

   2006 Estrogen-related receptors as emerging targets in cancer and metabolic disorders. Current Topics in Medicinal Chemistry 6 203–215.
5. ↵
   1. Ariazi EA,
   2. Clark GM &
   3. Mertz JE

   2002 Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Research 62 6510–6518.
6. ↵
   1. Asai-Sato M,
   2. Nagashima Y,
   3. Miyagi E,
   4. Sato K,
   5. Ohta I,
   6. Vonderhaar BK &
   7. Hirahara F

   2005 Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment. International Journal of Cancer 115 539–544.
7. ↵
   1. Bachman KE &
   2. Park BH

   2005 Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter. Current Opinion in Oncology 17 49–54.
8. ↵
   1. Bai Z &
   2. Gust R

   2009 Breast cancer, estrogen receptor and ligands. Archiv der Pharmazie 342 133–149.
9. ↵
   1. Bargou RC,
   2. Wagener C,
   3. Bommert K,
   4. Mapara MY,
   5. Daniel PT,
   6. Arnold W,
   7. Dietel M,
   8. Guski H,
   9. Feller A,
   10. Royer HD
   11. et al.

   1996 Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. Journal of Clinical Investigation 97 2651–2659.
10. ↵
    1. Belcher SM,
    2. Le HH,
    3. Spurling L &
    4. Wong JK

    2005 Rapid estrogenic regulation of extracellular signal- regulated kinase 1/2 signaling in cerebellar granule cells involves a G protein- and protein kinase A-dependent mechanism and intracellular activation of protein phosphatase 2A. Endocrinology 146 5397–5406.
11. ↵
    1. Bellail AC,
    2. Qi L,
    3. Mulligan P,
    4. Chhabra V &
    5. Hao C

    2009 TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Reviews on Recent Clinical Trials 4 34–41.
12. ↵
    1. Ben-Jonathan N &
    2. Steinmetz R

    1998 Xenoestrogens: the emerging story of bisphenol A. Trends in Endocrinology and Metabolism 9 124–128.
13. ↵
    1. Ben-Jonathan N,
    2. Mershon JL,
    3. Allen DL &
    4. Steinmetz RW

    1996 Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocrine Reviews 17 639–669.
14. ↵
    1. Ben-Jonathan N,
    2. Liby K,
    3. McFarland M &
    4. Zinger M

    2002 Prolactin as an autocrine/paracrine growth factor in human cancer. Trends in Endocrinology and Metabolism 13 245–250.
15. ↵
    1. Ben-Jonathan N,
    2. LaPensee CR &
    3. LaPensee EW

    2008 What can we learn from rodents about prolactin in humans? Endocrine Reviews 29 1–41.
16. ↵
    1. Birnbaum LS &
    2. Fenton SE

    2003 Cancer and developmental exposure to endocrine disruptors. Environmental Health Perspectives 111 389–394.
17. ↵
    1. Bjornstrom L &
    2. Sjoberg M

    2005 Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Molecular Endocrinology 19 833–842.
18. ↵
    1. Blanc C,
    2. Deveraux QL,
    3. Krajewski S,
    4. Janicke RU,
    5. Porter AG,
    6. Reed JC,
    7. Jaggi R &
    8. Marti A

    2000 Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Research 60 4386–4390.
19. ↵
    1. Bouskine A,
    2. Nebout M,
    3. Brucker-Davis F,
    4. Benahmed M &
    5. Fenichel P

    2009 Low doses of bisphenol A promote human seminoma cell proliferation by activating PKA and PKG via a membrane G-protein-coupled estrogen receptor. Environmental Health Perspectives 117 1053–1058.
20. ↵
    1. Brockman JL,
    2. Schroeder MD &
    3. Schuler LA

    2002 PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Molecular Endocrinology 16 774–784.
21. ↵
    1. Carver KC,
    2. Arendt LM &
    3. Schuler LA

    2009 Complex prolactin crosstalk in breast cancer: new therapeutic implications. Molecular and Cellular Endocrinology 307 1–7.
22. ↵
    1. Chakravarti P,
    2. Henry MK &
    3. Quelle FW

    2005 Prolactin and heregulin override DNA damage-induced growth arrest and promote phosphatidylinositol-3 kinase-dependent proliferation in breast cancer cells. International Journal of Oncology 26 509–514.
23. ↵
    1. Chang BD,
    2. Swift ME,
    3. Shen M,
    4. Fang J,
    5. Broude EV &
    6. Roninson IB

    2002 Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. PNAS 99 389–394.
24. ↵
    1. Chen WY,
    2. Ramamoorthy P,
    3. Chen N,
    4. Sticca R &
    5. Wagner TE

    1999 A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clinical Cancer Research 5 3583–3593.
25. ↵
    1. Chen NY,
    2. Holle L,
    3. Li W,
    4. Peirce SK,
    5. Beck MT &
    6. Chen WY

    2002 In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R. International Journal of Oncology 20 813–818.
26. ↵
    1. Clapp C,
    2. Thebault S &
    3. Martinez de la EG

    2008 Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland. Journal of Mammary Gland Biology and Neoplasia 13 55–67.
27. ↵
    1. Clevenger CV,
    2. Gadd SL &
    3. Zheng J

    2009 New mechanisms for PRLr action in breast cancer. Trends in Endocrinology and Metabolism 20 223–229.
28. ↵
    1. Coley HM

    2008 Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treatment Reviews 34 378–390.
29. ↵
    1. Dairkee SH,
    2. Seok J,
    3. Champion S,
    4. Sayeed A,
    5. Mindrinos M,
    6. Xiao W,
    7. Davis RW &
    8. Goodson WH

    2008 Bisphenol A induces a profile of tumor aggressiveness in high-risk cells from breast cancer patients. Cancer Research 68 2076–2080.
30. ↵
    1. Decatris MP,
    2. Sundar S &
    3. O'byrne KJ

    2004 Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treatment Reviews 30 53–81.
31. ↵
    1. Duan L,
    2. Sterba K,
    3. Kolomeichuk S,
    4. Kim H,
    5. Brown PH &
    6. Chambers TC

    2007 Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest. Biochemical Pharmacology 73 481–490.
32. ↵
    1. Duan R,
    2. Ginsburg E &
    3. Vonderhaar BK

    2008 Estrogen stimulates transcription from the human prolactin distal promoter through AP1 and estrogen responsive elements in T47D human breast cancer cells. Molecular and Cellular Endocrinology 281 9–18.
33. ↵
    1. Falconer IR

    2006 Are endocrine disrupting compounds a health risk in drinking water? International Journal of Environmental Research and Public Health 3 180–184.
34. ↵
    1. Ferlini C,
    2. Raspaglio G,
    3. Mozzetti S,
    4. Distefano M,
    5. Filippetti F,
    6. Martinelli E,
    7. Ferrandina G,
    8. Gallo D,
    9. Ranelletti FO &
    10. Scambia G

    2003 Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Molecular Pharmacology 64 51–58.
35. ↵
    1. Fernandez MF,
    2. Arrebola JP,
    3. Taoufiki J,
    4. Navalon A,
    5. Ballesteros O,
    6. Pulgar R,
    7. Vilchezb JL &
    8. Oleaa N

    2007 Bisphenol-A and chlorinated derivatives in adipose tissue of women. Reproductive Toxicology 24 259–264.
36. ↵
    1. Filardo EJ &
    2. Thomas P

    2005 GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends in Endocrinology and Metabolism 16 362–367.
37. ↵
    1. Filardo EJ,
    2. Quinn JA,
    3. Bland KI &
    4. Frackelton AR Jr.

    2000 Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Molecular Endocrinology 14 1649–1660.
38. ↵
    1. Filardo EJ,
    2. Graeber CT,
    3. Quinn JA,
    4. Resnick MB,
    5. Giri D,
    6. DeLellis RA,
    7. Steinhoff MM &
    8. Sabo E

    2006 Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clinical Cancer Research 12 6359–6366.
39. ↵
    1. Foster PA

    2008 Steroid metabolism in breast cancer. Minerva Endocrinologica 33 27–37.
40. ↵
    1. Fox EM,
    2. Andrade J &
    3. Shupnik MA

    2009 Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids 74 622–627.
41. ↵
    1. Friedrich K,
    2. Wieder T,
    3. Von Haefen C,
    4. Radetzki S,
    5. Janicke R,
    6. Schulze-Osthoff K,
    7. Dörken B &
    8. Daniel PT

    2001 Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene 20 2749–2760.
42. ↵
    1. Gerlo S,
    2. Davis JR,
    3. Mager DL &
    4. Kooijman R

    2006 Prolactin in man: a tale of two promoters. BioEssays 28 1051–1055.
43. ↵
    1. Gertler A,
    2. Grosclaude J,
    3. Strasburger CJ,
    4. Nir S &
    5. Djiane J

    1996 Real-time kinetic measurements of the interactions between lactogenic hormones and prolactin-receptor extracellular domains from several species support the model of hormone-induced transient receptor dimerization. Journal of Biological Chemistry 271 24482–24491.
44. ↵
    1. Goffin V,
    2. Bernichtein S,
    3. Touraine P &
    4. Kelly PA

    2005 Development and potential clinical uses of human prolactin receptor antagonists. Endocrine Reviews 26 400–422.
45. ↵
    1. Gonzalez L,
    2. Zambrano A,
    3. Lazaro-Trueba I,
    4. Lopez E,
    5. Gonzalez JJ,
    6. Martin-Perez J &
    7. Aranda A

    2009 Activation of the unliganded estrogen receptor by prolactin in breast cancer cells. Oncogene 28 1298–1308.
46. ↵
    1. Gray J,
    2. Evans N,
    3. Taylor B,
    4. Rizzo J &
    5. Walker M

    2009 State of the evidence: the connection between breast cancer and the environment. International Journal of Occupational and Environmental Health 15 43–78.
47. ↵
    1. Gutzman JH,
    2. Nikolai SE,
    3. Rugowski DE,
    4. Watters JJ &
    5. Schuler LA

    2005 Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos. Molecular Endocrinology 19 1765–1778.
48. ↵
    1. Henkels KM &
    2. Turchi JJ

    1999 Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Research 59 3077–3083.
49. ↵
    1. Hess-Wilson JK,
    2. Boldison J,
    3. Weaver KE &
    4. Knudsen KE

    2006 Xenoestrogen action in breast cancer: impact on ER-dependent transcription and mitogenesis. Breast Cancer Research and Treatment 96 279–292.
50. ↵
    1. Higgins CF

    2007 Multiple molecular mechanisms for multidrug resistance transporters. Nature 446 749–757.
51. ↵
    1. Howell SJ,
    2. Anderson E,
    3. Hunter T,
    4. Farnie G &
    5. Clarke RB

    2008 Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Research 10 R68.
52. ↵
    1. Hsu PC,
    2. Hour TC,
    3. Liao YF,
    4. Hung YC,
    5. Liu CC,
    6. Chang WH,
    7. Kao MC,
    8. Tsay G,
    9. Hung HC &
    10. Liu GY

    2006 Increasing ornithine decarboxylase activity is another way of prolactin preventing methotrexate-induced apoptosis: crosstalk between ODC and BCL-2. Apoptosis 11 389–399.
53. ↵
    1. Huang Y,
    2. Ray S,
    3. Reed JC,
    4. Ibrado AM,
    5. Tang C,
    6. Nawabi A &
    7. Bhalla K

    1997 Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Research and Treatment 42 73–81.
54. ↵
    1. Huang Y,
    2. Fang Y,
    3. Wu J,
    4. Dziadyk JM,
    5. Zhu X,
    6. Sui M &
    7. Fan W

    2004 Regulation of Vinca alkaloid-induced apoptosis by NF-kappaB/IkappaB pathway in human tumor cells. Molecular Cancer Therapeutics 3 271–277.
55. ↵
    1. Hugo ER,
    2. Brandebourg TD,
    3. Woo JG,
    4. Loftus J,
    5. Alexander JW &
    6. Ben-Jonathan N

    2008 Bisphenol A at environmentally relevant doses inhibits adiponectin release from human adipose tissue explants and adipocytes. Environmental Health Perspectives 116 1642–1647.
56. ↵
    1. Imai Y,
    2. Ishikawa E,
    3. Asada S &
    4. Sugimoto Y

    2005 Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Research 65 596–604.
57. ↵
    1. Jongen VH,
    2. Hollema H,
    3. Van Der Zee AG &
    4. Heineman MJ

    2006 Aromatase in the context of breast and endometrial cancer – a review. Minerva Endocrinologica 31 47–60.
58. ↵
    1. Kang JH,
    2. Kondo F &
    3. Katayama Y

    2006 Human exposure to bisphenol A. Toxicology 226 79–89.
59. ↵
    1. Karayiannakis AJ,
    2. Bastounis EA,
    3. Chatzigianni EB,
    4. Makri GG,
    5. Alexiou D &
    6. Karamanakos P

    1996 Immunohistochemical detection of oestrogen receptors in ductal carcinoma in situ of the breast. European Journal of Surgical Oncology 22 578–582.
60. ↵
    1. Kelland L

    2007 The resurgence of platinum-based cancer chemotherapy. Nature Reviews. Cancer 7 573–584.
61. ↵
    1. Kennedy RD,
    2. Quinn JE,
    3. Mullan PB,
    4. Johnston PG &
    5. Harkin DP

    2004 The role of BRCA1 in the cellular response to chemotherapy. Journal of the National Cancer Institute 96 1659–1668.
62. ↵
    1. Krishnan AV,
    2. Stathis P,
    3. Permuth SF,
    4. Tokes L &
    5. Feldman D

    1993 Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. Endocrinology 132 2279–2286.
63. ↵
    1. Kuiper GG,
    2. Lemmen JG,
    3. Carlsson B,
    4. Corton JC,
    5. Safe SH,
    6. van der Saag PT,
    7. van der Burg B &
    8. Gustafsson JA

    1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139 4252–4263.
64. ↵
    1. Lagadec C,
    2. Adriaenssens E,
    3. Toillon RA,
    4. Chopin V,
    5. Romon R,
    6. Van CF,
    7. Hondermarck H &
    8. Le Bourhis X

    2008 Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells. Oncogene 27 1472–1477.
65. ↵
    LaPensee EW, Fox S, Schwemberger SJ, Afton S & Ben-Jonathan N 2009a Bisphenol A and estradiol are equipotent in antagonizing cisplatin cytotoxicity in breast cancer cells. Cancer Letters [in press].
66. ↵
    1. LaPensee EW,
    2. Schwemberger SJ,
    3. LaPensee CR,
    4. Bahassi EM,
    5. Afton SE &
    6. Ben-Jonathan N

    2009b Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase. Carcinogenesis 30 1298–1304.
67. ↵
    1. LaPensee EW,
    2. Tuttle TR,
    3. Fox SR &
    4. Ben-Jonathan N

    2009c Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-alpha-positive and -negative breast cancer cells. Environmental Health Perspectives 117 175–180.
68. ↵
    1. Le HH,
    2. Carlson EM,
    3. Chua JP &
    4. Belcher SM

    2008 Bisphenol A is released from polycarbonate drinking bottles and mimics the neurotoxic actions of estrogen in developing cerebellar neurons. Toxicology Letters 176 149–156.
69. ↵
    1. L'Ecuyer T,
    2. Allebban Z,
    3. Thomas R &
    4. Vander HR

    2004 Glutathione-S-transferase overexpression protects against anthracycline-induced H9C2 cell death. American Journal of Physiology. Heart and Circulatory Physiology 286 H2057–H2064.
70. ↵
    1. Lewis-Wambi JS &
    2. Jordan VC

    2009 Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Research 11 206.
71. ↵
    1. Li X,
    2. Zhang S &
    3. Safe S

    2006 Activation of kinase pathways in MCF-7 cells by 17beta-estradiol and structurally diverse estrogenic compounds. Journal of Steroid Biochemistry and Molecular Biology 98 122–132.
72. ↵
    1. Liby K,
    2. Neltner B,
    3. Mohamet L,
    4. Menchen L &
    5. Ben-Jonathan N

    2003 Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Research and Treatment 79 241–252.
73. ↵
    1. Lissoni P,
    2. Vaghi M,
    3. Ardizzoia A,
    4. Fumagalli E,
    5. Tancini G,
    6. Gardani G,
    7. Conti A &
    8. Maestroni GJ

    2001 Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Neuroendocrinology Letters 22 27–29.
74. ↵
    1. Lissoni P,
    2. Bucovec R,
    3. Malugani F,
    4. Ardizzoia A,
    5. Villa S,
    6. Gardani GS,
    7. Vaghi M &
    8. Tancini G

    2002 A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines. Anticancer Research 22 1131–1134.
75. ↵
    1. Llovera M,
    2. Pichard C,
    3. Bernichtein S,
    4. Jeay S,
    5. Touraine P,
    6. Kelly PA &
    7. Goffin V

    2000 Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene 19 4695–4705.
76. ↵
    1. Luquita MG,
    2. Catania VA,
    3. Sanchez-Pozzi EJ,
    4. Vore M &
    5. Mottino AD

    1999 Prolactin increases the hepatic content of mu-class subunits of glutathione-S-transferase in the rat. Drug Metabolism and Disposition 27 122–124.
77. ↵
    1. Manavathi B &
    2. Kumar R

    2006 Steering estrogen signals from the plasma membrane to the nucleus: two sides of the coin. Journal of Cellular Physiology 207 594–604.
78. ↵
    1. Martin JH,
    2. Crotty S &
    3. Nelson PN

    2007 Phytoestrogens: perpetrators or protectors? Future Oncology 3 307–318.
79. ↵
    1. Maus MV,
    2. Reilly SC &
    3. Clevenger CV

    1999 Prolactin as a chemoattractant for human breast carcinoma. Endocrinology 140 5447–5450.
80. ↵
    1. McHale K,
    2. Tomaszewski JE,
    3. Puthiyaveettil R,
    4. Livolsi VA &
    5. Clevenger CV

    2008 Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Modern Pathology 21 565–571.
81. ↵
    1. McIlwain CC,
    2. Townsend DM &
    3. Tew KD

    2006 Glutathione-S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25 1639–1648.
82. ↵
    1. Mense SM,
    2. Hei TK,
    3. Ganju RK &
    4. Bhat HK

    2008 Phytoestrogens and breast cancer prevention: possible mechanisms of action. Environmental Health Perspectives 116 426–433.
83. ↵
    1. Nabholtz JM,
    2. Mouret-Reynier MA,
    3. Durando X,
    4. Van IP,
    5. Al-Sukhun S,
    6. Ferriere JP &
    7. Chollet P

    2009 Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer. Expert Opinion on Pharmacotherapy 10 1435–1447.
84. ↵
    1. Nevalainen MT,
    2. Xie J,
    3. Torhorst J,
    4. Bubendorf L,
    5. Haas P,
    6. Kononen J,
    7. Sauter G &
    8. Rui H

    2004 Signal transducer and activator of transcription-5 activation and breast cancer prognosis. Journal of Clinical Oncology 22 2053–2060.
85. ↵
    1. Nilsson S,
    2. Makela S,
    3. Treuter E,
    4. Tujague M,
    5. Thomsen J,
    6. Andersson G,
    7. Enmark E,
    8. Pettersson K,
    9. Warner M &
    10. Gustafsson JA

    2001 Mechanisms of estrogen action. Physiological Reviews 81 1535–1565.
86. ↵
    1. Normanno N,
    2. Di Maio M,
    3. De Maio E,
    4. De Luca A,
    5. de Matteis A,
    6. Giordano A,
    7. Perrone F &
    8. NCI-Naple Breast Cancer Group

    2005 Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocrine-Related Cancer 12 721–747.
87. ↵
    1. Ocana A &
    2. Pandiella A

    2008 Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options. Clinical Cancer Research 14 961–970.
88. ↵
    1. Okada H,
    2. Tokunaga T,
    3. Liu X,
    4. Takayanagi S,
    5. Matsushima A &
    6. Shimohigashi Y

    2008 Direct evidence revealing structural elements essential for the high binding ability of bisphenol A to human estrogen-related receptor-gamma. Environmental Health Perspectives 116 32–38.
89. ↵
    1. Olsen CM,
    2. Meussen-Elholm ET,
    3. Samuelsen M,
    4. Holme JA &
    5. Hongslo JK

    2003 Effects of the environmental oestrogens bisphenol A, tetrachlorobisphenol A, tetrabromobisphenol A, 4-hydroxybiphenyl and 4,4′-dihydroxybiphenyl on oestrogen receptor binding, cell proliferation and regulation of oestrogen sensitive proteins in the human breast cancer cell line MCF-7. Pharmacology and Toxicology 92 180–188.
90. ↵
    1. Pasqualini JR,
    2. Chetrite G,
    3. Blacker C,
    4. Feinstein MC,
    5. Delalonde L,
    6. Talbi M &
    7. Maloche C

    1996 Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. Journal of Clinical Endocrinology and Metabolism 81 1460–1464.
91. ↵
    1. Peirce SK,
    2. Chen WY &
    3. Chen WY

    2001 Quantification of prolactin receptor mRNA in multiple human tissues and cancer cell lines by real time RT-PCR. Journal of Endocrinology 171 R1–R4.
92. ↵
    1. Perks CM,
    2. Keith AJ,
    3. Goodhew KL,
    4. Savage PB,
    5. Winters ZE &
    6. Holly JM

    2004 Prolactin acts as a potent survival factor for human breast cancer cell lines. British Journal of Cancer 91 305–311.
93. ↵
    1. Perotti C,
    2. Liu R,
    3. Parusel CT,
    4. Bocher N,
    5. Schultz J,
    6. Bork P,
    7. Pfitzner E,
    8. Groner B &
    9. Shemanko CS

    2008 Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation. Breast Cancer Research 10 R94.
94. ↵
    1. Prossnitz ER,
    2. Arterburn JB,
    3. Smith HO,
    4. Oprea TI,
    5. Sklar LA &
    6. Hathaway HJ

    2008 Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annual Review of Physiology 70 165–190.
95. ↵
    1. Rabbani A,
    2. Finn RM &
    3. Ausio J

    2005 The anthracycline antibiotics: antitumor drugs that alter chromatin structure. BioEssays 27 50–56.
96. ↵
    1. Ramamoorthy P,
    2. Sticca R,
    3. Wagner TE &
    4. Chen WY

    2001 In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells. International Journal of Oncology 18 25–32.
97. ↵
    1. Razandi M,
    2. Pedram A &
    3. Levin ER

    2000 Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Molecular Endocrinology 14 1434–1447.
98. ↵
    1. Ricketts D,
    2. Turnbull L,
    3. Ryall G,
    4. Bakhshi R,
    5. Rawson NS,
    6. Gazet JC,
    7. Nolan C &
    8. Coombes RC

    1991 Estrogen and progesterone receptors in the normal female breast. Cancer Research 51 1817–1822.
99. ↵
    1. Riggins RB,
    2. Lan JP,
    3. Zhu Y,
    4. Klimach U,
    5. Zwart A,
    6. Cavalli LR,
    7. Haddad BR,
    8. Chen L,
    9. Gong T,
    10. Xuan J
    11. et al.

    2008 ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Research 68 8908–8917.
100. ↵
     1. Rodrik V,
     2. Zheng Y,
     3. Harrow F,
     4. Chen Y &
     5. Foster DA

     2005 Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc. Molecular and Cellular Biology 25 7917–7925.
101. ↵
     1. Ruffion A,
     2. Al Sakkaf KA,
     3. Brown BL,
     4. Eaton CL,
     5. Hamdy FC &
     6. Dobson PR

     2003 The survival effect of prolactin on PC3 prostate cancer cells. European Urology 43 301–308.
102. ↵
     1. Safe SH,
     2. Pallaroni L,
     3. Yoon K,
     4. Gaido K,
     5. Ross S &
     6. McDonnell D

     Problems for risk assessment of endocrine-active estrogenic compoundsEnvironmental Health Perspectives 110 Suppl 6 2002 925–929.
103. ↵
     1. Samuelsen M,
     2. Olsen C,
     3. Holme JA,
     4. Meussen-Elholm E,
     5. Bergmann A &
     6. Hongslo JK

     2001 Estrogen-like properties of brominated analogs of bisphenol A in the MCF-7 human breast cancer cell line. Cell Biology and Toxicology 17 139–151.
104. ↵
     1. Santen RJ,
     2. Santner SJ,
     3. Pauley RJ,
     4. Tait L,
     5. Kaseta J,
     6. Demers LM,
     7. Hamilton C,
     8. Yue W &
     9. Wang JP

     1997 Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? Journal of Steroid Biochemistry and Molecular Biology 61 267–271.
105. ↵
     1. Sessa C,
     2. Guibal A,
     3. Del CG &
     4. Ruegg C

     2008 Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nature Clinical Practice and Oncology 5 378–391.
106. ↵
     1. Shaaban AM,
     2. O'Neill PA,
     3. Davies MP,
     4. Sibson R,
     5. West CR,
     6. Smith PH &
     7. Foster CS

     2003 Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. American Journal of Surgical Pathology 27 1502–1512.
107. ↵
     1. Shiga H,
     2. Heath EI,
     3. Rasmussen AA,
     4. Trock B,
     5. Johnston PG,
     6. Forastiere AA,
     7. Langmacher M,
     8. Baylor A,
     9. Lee M &
     10. Cullen KJ

     1999 Prognostic value of p53, glutathione-S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clinical Cancer Research 5 4097–4104.
108. ↵
     1. Siddik ZH

     2003 Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 7265–7279.
109. ↵
     1. Simoes-Wust AP,
     2. Schurpf T,
     3. Hall J,
     4. Stahel RA &
     5. Zangemeister-Wittke U

     2002 Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Research and Treatment 76 157–166.
110. ↵
     1. Singleton DW,
     2. Feng Y,
     3. Chen Y,
     4. Busch SJ,
     5. Lee AV,
     6. Puga A &
     7. Khan SA

     2004 Bisphenol-A and estradiol exert novel gene regulation in human MCF-7 derived breast cancer cells. Molecular and Cellular Endocrinology 221 47–55.
111. ↵
     1. Song RX,
     2. Fan P,
     3. Yue W,
     4. Chen Y &
     5. Santen RJ

     Role of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancerEndocrine-Related Cancer 13 Suppl 1 2006 S3–S13.
112. ↵
     1. Sui M,
     2. Huang Y,
     3. Park BH,
     4. Davidson NE &
     5. Fan W

     2007 Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Research 67 5337–5344.
113. ↵
     1. Sultan AS,
     2. Xie J,
     3. LeBaron MJ,
     4. Ealley EL,
     5. Nevalainen MT &
     6. Rui H

     2005 Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 24 746–760.
114. ↵
     1. Suzuki T,
     2. Miki Y,
     3. Nakamura Y,
     4. Moriya T,
     5. Ito K,
     6. Ohuchi N &
     7. Sasano H

     2005 Sex steroid-producing enzymes in human breast cancer. Endocrine-Related Cancer 12 701–720.
115. ↵
     1. Swaminathan G,
     2. Varghese B &
     3. Fuchs SY

     2008 Regulation of prolactin receptor levels and activity in breast cancer. Journal of Mammary Gland Biology and Neoplasia 13 81–91.
116. ↵
     1. Tanabe N,
     2. Kimoto T &
     3. Kawato S

     2006 Rapid Ca(2+) signaling induced by bisphenol A in cultured rat hippocampal neurons. Neuroendocrinology Letters 27 97–104.
117. ↵
     1. Teilum K,
     2. Hoch JC,
     3. Goffin V,
     4. Kinet S,
     5. Martial JA &
     6. Kragelund BB

     2005 Solution structure of human prolactin. Journal of Molecular Biology 351 810–823.
118. ↵
     1. Teixeira C,
     2. Reed JC &
     3. Pratt MA

     1995 Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Research 55 3902–3907.
119. ↵
     1. Thomas P,
     2. Pang Y,
     3. Filardo EJ &
     4. Dong J

     2005 Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146 624–632.
120. ↵
     1. Touraine P,
     2. Martini JF,
     3. Zafrani B,
     4. Durand JC,
     5. Labaille F,
     6. Malet C,
     7. Nicolas A,
     8. Trivin C,
     9. Postel-Vinay MC,
     10. Kuttenn F
     11. et al.

     1998 Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. Journal of Clinical Endocrinology and Metabolism 83 667–674.
121. ↵
     1. Townsend DM &
     2. Tew KD

     2003 The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22 7369–7375.
122. ↵
     1. Trock BJ,
     2. Leonessa F &
     3. Clarke R

     1997 Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. Journal of the National Cancer Institute 89 917–931.
123. ↵
     1. Tworoger SS &
     2. Hankinson SE

     2008 Prolactin and breast cancer etiology: an epidemiologic perspective. Journal of Mammary Gland Biology and Neoplasia 13 41–53.
124. ↵
     1. Utama FE,
     2. LeBaron MJ,
     3. Neilson LM,
     4. Sultan AS,
     5. Parlow AF,
     6. Wagner KU &
     7. Rui H

     2006 Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice. Journal of Endocrinology 188 589–601.
125. ↵
     1. Vacca A,
     2. Iurlaro M,
     3. Ribatti D,
     4. Minischetti M,
     5. Nico B,
     6. Ria R,
     7. Pellegrino A &
     8. Dammacco F

     1999 Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94 4143–4155.
126. ↵
     1. Van Den Bemd GJ,
     2. Kuiper GG,
     3. Pols HA &
     4. Van Leeuwen JP

     1999 Distinct effects on the conformation of estrogen receptor alpha and beta by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. Biochemical and Biophysical Research Communications 261 1–5.
127. ↵
     1. Vonderhaar BK

     1999 Prolactin involvement in breast cancer. Endocrine-Related Cancer 6 389–404.
128. ↵
     1. Walsh DE,
     2. Dockery P &
     3. Doolan CM

     2005 Estrogen receptor independent rapid non-genomic effects of environmental estrogens on [Ca²⁺]i in human breast cancer cells. Molecular and Cellular Endocrinology 230 23–30.
129. ↵
     1. Wang S &
     2. El Deiry WS

     2003 TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22 8628–8633.
130. ↵
     1. Wang Z,
     2. Goulet R III.,
     3. Stanton KJ,
     4. Sadaria M &
     5. Nakshatri H

     2005 Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Research 25 2367–2379.
131. ↵
     1. Watson CS,
     2. Bulayeva NN,
     3. Wozniak AL &
     4. Finnerty CC

     2005 Signaling from the membrane via membrane estrogen receptor-alpha: estrogens, xenoestrogens, and phytoestrogens. Steroids 70 364–371.
132. ↵
     1. Watson CS,
     2. Bulayeva NN,
     3. Wozniak AL &
     4. Alyea RA

     2007 Xenoestrogens are potent activators of nongenomic estrogenic responses. Steroids 72 124–134.
133. ↵
     1. Welshons WV,
     2. Nagel SC &
     3. vom Saal FS

     2006 Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure. Endocrinology 147 S56–S69.
134. ↵
     1. Wiltshire T,
     2. Senft J,
     3. Wang Y,
     4. Konat GW,
     5. Wenger SL,
     6. Reed E &
     7. Wang W

     2007 BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven. Molecular Pharmacology 71 1051–1060.
135. ↵
     1. Yde CW &
     2. Issinger OG

     2006 Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1. International Journal of Oncology 29 1397–1404.
136. ↵
     1. Zampieri L,
     2. Bianchi P,
     3. Ruff P &
     4. Arbuthnot P

     2002 Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells. Anticancer Research 22 2253–2259.
137. ↵
     1. Zhou J &
     2. Giannakakou P

     2005 Targeting microtubules for cancer chemotherapy. Current Medicinal Chemistry: Anti-Cancer Agents 5 65–71.
138. ↵
     1. Zinger M,
     2. McFarland M &
     3. Ben-Jonathan N

     2003 Prolactin expression and secretion by human breast glandular and adipose tissue explants. Journal of Clinical Endocrinology and Metabolism 88 689–696.